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Abstracts / Osteoarthritis and Cartilage 20 (2012) S54–S296S178JSN scores, medially or laterally. Progression was compartment speciﬁc for
the various clusters. Medial progression occurred only in clusters 1, 2 and
4, most dramatically so in cluster 4 (48%). Cluster 3 again only showed
lateral progression (61%).
Conclusions: We found clear differences between the various clusters.
Cluster 1 could be described as amild type of OA,with nodenuded bone and
limited OA progression. Cluster 3 and 4weremore severe and erosive types
of OA, showing strong increases in area of denudedbonewith increasingOA
severity, and a high prevalence of progression. Interestingly, cluster 3 was
purely a lateral type of OA, while cluster 4was purelymedial in all respects.
The causes that led to differences between the clusters remain speculative.
The higher prevalence of reported trauma in cluster 3 and 4, the more
aggressive OA types might suggest a difference in OA initiation.
Wekept the complexityof themodels lowtoreduce the riskofoverﬁttingand
increase the likelihood that our ﬁndings are generalizable to other cohorts.
The fact that clusters also differed on data not included in cluster ﬁnding
(trauma and progression) indicates that the found clusters are meaningful.
In conclusion, latent class cluster analysis conﬁrmed the suspected exis-
tence of distinct subtypes of knee OA.
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Purpose: Osteoarthritis (OA) treatment is often unsatisfactory, with
limited data suggesting that inadequate pain relief (IPR) is a major issue for
people with OA. Despite multiple medication options, data on treatment
patterns, adequacy of pain relief and quality of life are limited. SORT was
designed to determine the adequacy of pain relief and compare clinical
characteristics and patient-reported outcomes in patients with knee OA.
Methods: SORT, a 12-month prospective, observational study enrolled
1,260 participants (across 6 EU countries) who used oral and/or topical
agents. People > 50 years old with knee OA visiting a primary care
physician and taking pain medications in the past 14 days were enrolled.
Clinical history, medications, quality of life, treatment satisfaction and
health care resource utilization were collected at baseline and months 1, 3,
6, 9 and 12. IPR was deﬁned as an average Brief Pain Inventory pain score of
"moderate or greater pain" (score >4). Baseline data are presented in this
analysis.
Results: Evaluable baseline data are presented for 1025 participants: 68%
women; median age 67 years; duration of knee OA for 5.5 years (SD¼6.2)and 67% were taking oral pain medications, 14% were taking topical or
a combination of oral and topical agents. Hypertension (50%) was the most
common co-morbidity. IPR was reported by 54% of the cohort (558 of
1025). Participants reporting IPR were clinically different than non-IPR
participants having greater BMI (30.3 vs. 28.7 kg/m2, p< 0.001); duration
of disease (6.2 yrs vs. 4.8yrs, p <0.001) and proportion with OA of both
knees (55% vs. 39%, p<0.001). Overall, the analgesics used most oftenwere
NSAIDs (64.1%); followed by paracetamol (39.8%), medications containing
opioids (20.2%) and alternative therapies (12.6%). IPR participants (vs. non-
IPR) used more opioid containing medications (24.7% vs. 14.8%, p< 0.001).
IPR participants (vs. non-IPR) differed in their scoring on: WOMAC Stiff-
ness (115 vs. 67, p< 0.001), Pain (266 vs. 136, p< 0.001), Physical Function
(892 vs. 459, p<0.001); SF-12 General Health (fair/poor 47% vs. 27%,
p<0.001); satisfaction with prescribed knee OA treatment (less than
satisﬁed 59% vs. 36%, p<0.001) and satisfactionwith treatment side effects
(less than satisﬁed 41% vs. 23%, p<0.001). Additionally, there were
signiﬁcant differences in IPR participants' report of response to prescribed
medication (fair, poor and no response 67% vs. 43%, p<0.001) as compared
to non-IPR. IPR vs. non-IPR participants differed signiﬁcantly in the
number of GP/family physician visits for knee OA (p<0.023) and number of
physician visits for other reasons (p<0.011). More IPR participants repor-
ted having "more than one visit" to a physician for knee OA and other
reasons than non-IPR participants.
Conclusions: SORT, an observation of real world clinical practice, found
over half of those being treated for knee OA had persistent moderate to
severe pain. IPR was associated with higher BMI, longer disease duration,
multiple site OA, greater opioid use and more health-care resource utili-
zation.
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BODYWEIGHT CHANGES AND CORRESPONDING CHANGES IN PAIN AND
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A LONGITUDINAL ANALYSIS USING DATA FROM OAI AND MOST
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Purpose: Osteoarthritis (OA) of the knee has multiple causes but one of the
more powerful risk factors for OA onset and progression is excessive
bodyweight. We found no studies that determined if a dose-response
relationship existed between bodyweight changes, both gains and losses,
and changes in knee related pain and functional status in a large sample of
persons with symptomatic knee osteoarthritis. Trial evidence suggests that
weight loss of at least 5% of body weight would lead to improved function
and that weight losses of 10% or more would lead to greater reductions in
pain and substantially improved function. Recommendations based on
trial ﬁndings on persons with knee OA are similar to federal government-
based recommendations for weight loss to optimize health. The purpose of
our study was to determine if a dose-response relationship exists between
percentage bodyweight changes in persons with symptomatic knee oste-
oarthritis (OA) and self reported pain and function.
Methods: Data from persons in the Osteoarthritis Initiative (OAI) and the
Multicenter Osteoarthritis (MOST) datasets (n¼1410) with symptomatic
function limiting knee OAwere studied. For the OAI, we used baseline and
3-year follow-up data while for the MOST, baseline and 30-month data
were used. Key outcome variables were WOMAC Physical Function and
Pain change scores. In addition to covariates, the predictor variable of
interest was the extent of weight change over the study period and divided
into 5 categories representing different percentages of bodyweight
change.
Results: A signiﬁcant dose-response relationship (p< 0.001) was found
between the extent of percentage change in bodyweight and the extent of
change in WOMAC Physical Function and WOMAC Pain. For example,
persons who gained >10% of bodyweight had WOMAC Physical Function
score changes of -5.4 (95%CI, -8.7, -2.00) points indicating worsening
relative to the reference group of persons with weight changes of between
<5% weight gain and <5% weight loss.
Conclusions: Our data provide the ﬁrst published evidence to suggest
a dose-response relationship between changes in bodyweight and corre-
sponding changes in pain and function. The threshold for this response
gradient appears to be >10% bodyweight shifts. Clinicians can advise
